The influence of some MAO inhibitors and neuroleptics on enzymes concerned in GABA metabolism.
D000613:Aminobutyrates / Q000378:metabolism*; D000639:Amitriptyline / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000201:enzymology* / Q000378:metabolism; D002262:Carboxy-Lyases / Q000378:metabolism*; D002746:Chlorpromazine / Q000494:pharmacology; D005971:Glutamates / Q000378:metabolism*; D006834:Hydrazines / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010293:Pargyline / Q000494:pharmacology; D010624:Phenelzine / Q000494:pharmacology; D014191:Tranylcypromine / Q000494:pharmacology
D000613:Aminobutyrates; D000928:Antidepressive Agents; D005971:Glutamates; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D000639:Amitriptyline; D014191:Tranylcypromine; D010293:Pargyline; D002262:Carboxy-Lyases; D010624:Phenelzine; D007099:Imipramine; D002746:Chlorpromazine